DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer today announced that avelumab* presentations across seven different tumor types, including two oral presentations, will be featured at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3–7, 2016, in Chicago, IL. The avelumab presentations, from the rapidly accelerating JAVELIN clinical development program, include new study results from a number of difficult-to-treat can
![]()
↧